SELLAS Life Sciences Group Inc (SLS)

[LiveLife]

Phase 1/2 clinical trial news - https://immuno-oncologynews.com/2019/10/18/first-patients-dosed-in-phase-1-2-trial-testing-galinpepimut-s-keytruda-combo-in-advanced-cancers/

"A Phase 1/2 clinical trial assessing the cancer vaccine galinpepimut-S in combination with Keytruda (pembrolizumab) as a treatment for WT-1-positive advanced cancers has started dosing patients, Sellas Life Sciences announced.

Galinpepimut-S is a cancer vaccine developed by Sellas to target the Wilms tumor 1 (WT1) protein. WT1 is found at high levels in several cancers and is considered the No. 1 target for cancer immunotherapy by the National Cancer Institute.

Originally developed by researchers at the Memorial Sloan Kettering Cancer Center, galinpepimut-S consists of four small proteins that elicit a strong immune response against WT-1. It also creates a kind of immune memory, allowing the immune system to eliminate cancer cells that return after treatment.

Keytruda is a so-called immune checkpoint inhibitor, which works by blocking the interaction between the PD-1 protein on immune T-cells with the PD-L1 protein on cancer cells. Cancers often use this interaction to inhibit the function of immune cells, thus Keytruda works to boost the body’s own immune system ..."

SLS moved to BUY on Swing Trading board - https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151787386